AVROBIO Signals Major Corporate Changes, Potential Control Shift

TL;DR

**AVROBIO just dropped an 8-K hinting at big changes, possibly a sale or major deal.**

AI Summary

AVROBIO, Inc. filed an 8-K on January 30, 2024, indicating significant corporate changes, including entry into a material definitive agreement, potential changes in control, and alterations to director and officer compensation. This filing suggests a major strategic shift or transaction is underway, which could impact the company's future direction and financial health. For shareholders, this matters because such events often lead to substantial stock price movements, either positive or negative, depending on the nature and terms of the agreements.

Why It Matters

This filing signals that AVROBIO is undergoing significant corporate restructuring or a transaction, which could fundamentally alter its business operations, ownership, and ultimately, its stock valuation.

Risk Assessment

Risk Level: high — The filing indicates potential changes in control and material agreements, which introduce significant uncertainty and risk regarding the company's future.

Analyst Insight

A smart investor would closely monitor AVROBIO's subsequent filings and press releases for specific details regarding the 'Material Definitive Agreement' and 'Changes in Control of Registrant' to assess the impact on the company's valuation and future prospects before making any investment decisions.

Key Players & Entities

• AVROBIO, Inc. (company) — the registrant filing the 8-K
• January 30, 2024 (date) — date of earliest event reported
• 001-38537 (string) — Commission File Number

Forward-Looking Statements

• AVROBIO will announce details of a material definitive agreement. (AVROBIO, Inc.) — high confidence, target: Q1 2024
• There will be changes in the composition of AVROBIO's board or executive team. (AVROBIO, Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share AVRO Nasdaq Glo
• $130.7 m — ed below in the amount of approximately $130.7 million, on a pro forma basis, based upon
• $64.5 million — AVRO's net cash at closing is less than $64.5 million or greater than $65.5 million, as furth
• $65.5 m — less than $64.5 million or greater than $65.5 million, as further described in the Merg
• $114,500,000 — ggregate cash proceeds of not less than $114,500,000 to Tectonic, (6) absence of material ad
• $50,000,000 — (7) AVRO's net cash not being less than $50,000,000 as of immediately prior to the Effectiv
• $2,712,500 — ed to pay Tectonic a termination fee of $2,712,500 and/or reimburse Tectonic's expenses up
• $650,000 — Tectonic's expenses up to a maximum of $650,000, and Tectonic may be required to pay AV
• $4,900,000 — quired to pay AVRO a termination fee of $4,900,000. At the Effective Time of the Merger,
• $130.7 million — e "SAFEs"), are expected to be at least $130.7 million in the aggregate. The closing of the pr

Filing Documents

• d221662d8k.htm (8-K) — 60KB
• d221662dex21.htm (EX-2.1) — 623KB
• d221662dex101.htm (EX-10.1) — 53KB
• d221662dex102.htm (EX-10.2) — 44KB
• d221662dex103.htm (EX-10.3) — 30KB
• d221662dex104.htm (EX-10.4) — 107KB
• d221662dex991.htm (EX-99.1) — 30KB
• 0001193125-24-018812.txt ( ) — 1310KB
• avro-20240130.xsd (EX-101.SCH) — 3KB
• avro-20240130_lab.xml (EX-101.LAB) — 18KB
• avro-20240130_pre.xml (EX-101.PRE) — 11KB
• d221662d8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K and the exhibits filed or furnished herewith contain "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding the structure, timing and completion of the Merger; the combined company's listing on Nasdaq after the closing of the proposed Merger (the "Closing"); expectations regarding the ownership structure of the combined company; the anticipated timing of the Closing; the expected executive officers and directors of the combined company; expectations regarding the structure, amount, timing and completion of private placement financings, including investment amounts from investors, timing of closing, expected proceeds and impact on ownership structure; each company's and the combined company's expected cash position at the Closing and cash runway of the combined company following the Merger and private financing; the future operations of the combined company, including commercialization activities, timing of launch, buildout of commercial infrastructure; the nature, strategy and focus of the combined company; the development and commercial potential and potential benefits of any product candidates of the combined company,; the location of the combined company's corporate headquarters; anticipated clinical drug development activities and related timelines; and other statements that are not historical fact. All statements other than statements of historical fact contained in this Current Report on Form 8-K and the exhibits filed or furnished herewith are forward-looking statements. These forward-looking statements are made as of the date they were first issued, and were based on the then-current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management. There can be no assurance that future developments affecting

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 2.1* Agreement and Plan of Merger, dated as of January 30, 2024, by and among AVRO, Aspen Merger Subsidiary, Inc. and Tectonic. 10.1 Form of Tectonic Support Agreement 10.2 Form of AVRO Support Agreement 10.3 Form of Lock-Up Agreement 10.4 Form of Contingent Value Rights Agreement 99.1 Joint Press Release, issued on January 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided , however , that the registrant may request confidential treatment pursuant to Rule 24b-2 under the Exchange Act for any exhibits or schedules so furnished.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVROBIO, INC. Date: January 30, 2024 By: /s/ Erik Ostrowski Erik Ostrowski President, Interim Chief Executive Officer, Chief Financial Officer and Treasurer

View Full Filing

View this 8-K filing on SEC EDGAR